Program
GW5282
A development code. Also written as “GW5282 combined with Golidocitinib”.
Its studies are mostly in Lymphoma, T-Cell, led by Dizal Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Dizal Pharmaceuticals | 22 open or running | phase 2since Dec 26, 2025 | Dec 26, 2025 | Dec 2028phase 2 · NCT07328217 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 26, 2025First study: phase 2 study in Advanced Solid TumorsFirst studyNCT07328217 · 203 planned · China
- Mar 16, 2026Phase 2 study in Lymphoma, T-CellNCT07496229 · 220 planned · China
Ahead
- Dec 2028Primary completion: phase 2 study in Advanced Solid TumorsNCT07328217
- Sep 2029Primary completion: phase 2 study in Lymphoma, T-CellNCT07496229
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07496229Lymphoma, T-Cell · China | 2 | Recruiting | Sep 2029 | 220 |
| NCT07328217Advanced Solid Tumors · China | 2 | Recruiting | Dec 2028 | 203 |
How it is read
Names in the registry
- “GW5282 combined with Golidocitinib”, 3 entries
- “GW5282”, 2 entries
Codes read as this program: GW5282.
Conditions, from the studies’ own filings
- Lymphoma, T-Cell, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.